Resources

TechBio's 2024 breakthroughs proved it’s not just innovating—it’s transforming healthcare, with the UK leading the charge into a future where biology, tech, and data redefine possibilities.

The BIA is driving progress across life sciences, from shaping policy in engineering biology and advocating for balanced perspectives in the Covid Inquiry to exhibiting UK innovation at J.P. Morgan Healthcare Week. 

The UK’s Cell and Gene Therapy Catapult has published new insights into the advancement of the UK’s cell and gene therapy industry in its 2024 ATMP Clinical Trials Database.

United Kingdom National Nuclear Laboratory and Medicines Discovery Catapult have received funding to drive the development of innovative approaches for new cancer treatments.

As a significant milestone in the University’s history as an apprenticeship provider, Manchester Met’s Laboratory Scientist (Bioscience) Degree Apprenticeship has become the first Level 6 apprenticeship to be accredited by the Royal Society of Biology (RSB).

As we bid a fond farewell to Christiane Abouzeid after over 20 years of outstanding service to the BioIndustry Association, we are also thrilled to announce new leadership changes within our Policy and Public Affairs team.

£20 million Series A financing underway to support development of lead product

Chromatin Bioscience is pleased to announce its ongoing collaboration with EsoBiotec, which has successfully advanced its ESO-T01 in vivo CAR-T candidate into clinical trials.

In this blog, Maddie Cass, Senior Policy and Public Affairs Executive at the BIA, shares our perspective on the recent EngBio public trust survey findings conducted by the DSIT.

New St John’s innovation centre strengthens support for technology and life sciences sectors.

The International R&D Tax Guide is a comprehensive resource designed to assist businesses in understanding and leveraging R&D tax incentives across various jurisdictions.

Touchlight’s dbDNA technology is the first synthetic DNA technology to receive a GMP certificate globally.

Matthew has over 25 years’ experience in drug discovery and development across multiple target classes covering oncology, immunology, neurology, ophthalmology and metabolic disease. He joins from Storm Therapeutics — where he was Senior Vice President of Therapeutics.

Nxera Pharma reports significant progress on its partnered muscarinic agonist portfolio with Neurocrine Biosciences, including plans for Phase 3 schizophrenia trials and multiple Phase 2 studies in 2025.

Johnson & Johnson has agreed to acquire Intra-Cellular Therapies for $14.6 billion, adding its innovative schizophrenia and bipolar treatment CAPLYTA® to J&J's neuroscience portfolio, along with a promising pipeline of therapies.

A new biotech venture is advancing best-in-class oral and injectable therapies for obesity and cardiometabolic disorders, backed by $411 million in funding from leading global investors.

GSK has announced the acquisition of IDRX-42, a next-generation KIT tyrosine kinase inhibitor (TKI). This $1.15 billion deal strengthens GSK’s portfolio in gastrointestinal cancers.

‘Gastronomica’ is the brainchild of Pioneer Group, which specialises in life science infrastructure and venture-building. The incubator is being created through a cooperation between Pioneer and Unilever.

Medicines Discovery Catapult (MDC), a national Life Sciences service dedicated to driving productivity and impact in drug R&D, has strengthened its Executive team with the appointment of a Chief Commercial Officer and its first Managing Director.